Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Rocket Pharmaceuticals, Inc. (RCKT : NSDQ)

• Company Description    Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company. It focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket Pharmaceuticals Inc., formerly known as Inotek Pharmaceuticals Corporation, is based in LEXINGTON, United States. Number of Employees: 299

• Price / Volume Information    Yesterday's Closing Price: $2.53 Daily Weekly Monthly 20 Day Moving Average: 4,641,105 shares Shares Outstanding: 106.79 (millions) Market Capitalization: $270.17 (millions) Beta: 0.69 52 Week High: $26.98 52 Week Low: $2.19 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.80% -3.47% 12 Week -50.59% -59.38% Year To Date -79.87% -80.82%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 9 Cedarbrook Drive - Cranbury,NJ 08512 USA ph: 609-659-8001 fax: 646-224-9585 mdodge@rocketpharma.com http://www.rocketpharma.com

• General Corporate Information    Officers Gaurav Shah - Chief Executive Officer and Director Aaron Ondrey - Chief Financial Officer John Militello - Vice President; Finance; Senior Controller Elisabeth Bjork - Director Carsten Boess - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 77313F106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/04/25 Share - Related Items Shares Outstanding: 106.79 Most Recent Split Date: 1.00 (0.25:1) Beta: 0.69 Market Capitalization: $270.17 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.57 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.23 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 10.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.66 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 15.15% vs. Previous Quarter: 9.68% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/25 - -64.92 12/31/24 - -63.92 09/30/24 - -62.62 ROA 03/31/25 - -56.13 12/31/24 - -55.43 09/30/24 - -54.17 Current Ratio 03/31/25 - 9.19 12/31/24 - 9.30 09/30/24 - 6.05 Quick Ratio 03/31/25 - 9.19 12/31/24 - 9.30 09/30/24 - 6.05 Operating Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Net Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Pre-Tax Margin 03/31/25 - - 12/31/24 - - 09/30/24 - - Book Value 03/31/25 - 3.86 12/31/24 - 5.08 09/30/24 - 3.62 Inventory Turnover 03/31/25 - - 12/31/24 - - 09/30/24 - - Debt-to-Equity 03/31/25 - 0.05 12/31/24 - 0.04 09/30/24 - 0.06 Debt-to-Capital 03/31/25 - 4.49 12/31/24 - 4.02 09/30/24 - 5.55

Powered by Zacks Investment Research ©